Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin biosimilar - Biopartners/LG Chem

Drug Profile

Somatropin biosimilar - Biopartners/LG Chem

Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin Biopartners; Somatropina Biopartners; SR-rhGH; Valtropin

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer Biopartners GmbH; LG Chem; LG Life Sciences; Merck KGaA
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Phase III Prader-Willi syndrome

Most Recent Events

  • 03 Aug 2017 Phase-II development for Short stature (In children, Treatment-naive) is ongoing in South Korea (SC, Controlled release)
  • 03 Aug 2017 Somatropin biosimilar is still in phase III trials for Prader-Willi syndrome (In children, In adults, In the elderly) in South Korea (SC, injection) (NCT02204163)
  • 02 Aug 2017 No recent reports on development identified - Registered for Somatotropin deficiency (In children, In adults) in Norway, Iceland and Liechtenstein (SC, controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top